Answers are grounded in this paper and cite their sources.
Fidaxomicin provides improved sustained cure rates in patients with CDI compared with vancomycin. An indirect comparison indicates that the same is also true for fidaxomicin versus metronidazole. In view of these data, fidaxomicin may be considered as first-line therapy for CDI.
No takes yet. Share an insight, caveat, or question.
Cornely et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: